Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aspira Womens Health's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-2.37 Mil. Aspira Womens Health's Total Assets for the quarter that ended in Dec. 2023 was $6.26 Mil.
Therefore, Aspira Womens Health's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.38.
The historical rank and industry rank for Aspira Womens Health's Equity-to-Asset or its related term are showing as below:
AWH'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.38 Med: 0.56 Max: 0.84
Current: -0.38
During the past 13 years, the highest Equity to Asset Ratio of Aspira Womens Health was 0.84. The lowest was -0.38. And the median was 0.56.
AWH's Equity-to-Asset is ranked worse than 91.56% of 237
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58
vs AWH: -0.38
Aspira Womens Health Equity-to-Asset Historical Data
The historical data trend for Aspira Womens Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aspira Womens Health's Equity-to-Asset
For the Diagnostics & Research subindustry, Aspira Womens Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Equity-to-Asset falls into.
Aspira Womens Health Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aspira Womens Health's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (NAS:AWH) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aspira Womens Health Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (Aspira Womens Health) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AWH has been successfully added to your 